CuraVac is an innovative company founded to take a newly discovered technique for creating therapeutic vaccines against autoimmune diseases from discovery through to being available for treatment of humans.

Typical autoimmune diseases that should be treatable by CuraVac vaccines include myasthenia gravis, multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosis.

Through this web site, CuraVac aims to bring its activities to the attention of the wider public who wants to know about CuraVac and its team and to offer an investment or donation opportunity to those who wish to support its work.

In 2009, the myasthenia gravis therapeutic vaccine, the first vaccine in a series, was granted Orphan Drug Designation in Europe by a team of 27 independent experts of the 27 European member states.

In 2011, the MG therapeutic vaccine was granted Orphan Drug Designation in the USA by the FDA.

In 2013, following a call for proposals that was answered by all the best medicine projects in the world, CuraVac’s project for a MG therapeutic vaccine was one of the 7 therapeutic vaccine projects that were selected by an Independent Jury Committee of the best world experts.

Curavac created a European consortium of four companies and one University Medical Center that receives the support of the FP7 2013 Health Innovation to conduct clinical trials of the MG therapeutic vaccine : MYASTERIX.

In November 2015 the Phase 1B clinical trial of the MG Therapeutic Vaccine started at the Antwerp University Hospital.  The preliminary results were communicated at the 13th Internationnal Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science in May 2017.

The final results of  the phase 1b  communicated in June 2018 demonstrate an excellent safety profile and call for a phase 2 efficacy clinical trial  with a more potent formulation.  


They didn’t know it was impossible so they did it” (Mark Twain)